Stephanie Lupton

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab

Simeng Lin, Nicholas A. Kennedy, Aamir Saifuddin et al. · Nature Communications · 2022 · 81 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study

Zhigang Liu, Kaixing Le, Xin Zhou et al. · ˜The œLancet. Gastroenterology & hepatology · 2022 · 35 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Using trained dogs and organic semi-conducting sensors to identify asymptomatic and mild SARS-CoV-2 infections: an observational study

Claire Guest, Sarah Y. Dewhirst, Steve W. Lindsay et al. · Journal of Travel Medicine · 2022 · 28 citations · Full text

Medicine, Infectious Diseases, Biosensors +14

Implications for sequencing of biologic therapy and choice of second <scp>anti‐TNF</scp> in patients with inflammatory bowel disease: results from the <scp>IMmunogenicity</scp> to Second <scp>Anti‐TNF</scp> therapy (<scp>IMSAT</scp>) therapeutic drug monitoring study

Neil Chanchlani, Simeng Lin, Marcus Auth et al. · Alimentary Pharmacology & Therapeutics · 2022 · 17 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Exploring the role of gender and gendered pain expectation in physiotherapy students

Marudan Sivagurunathan, Joy C. MacDermid, Joseph Chien Yee Chuang et al. · Canadian Journal of Pain · 2019 · 10 citations · Full text

Social Sciences, Gender Studies, Gender +11